{
    "clinical_study": {
        "@rank": "30194", 
        "acronym": "NEWEAR", 
        "arm_group": {
            "arm_group_label": "chemoradiotherapy, S1, oxaliplatin", 
            "arm_group_type": "Experimental", 
            "description": "chemoradiotherapy is given before surgical therapy,S1(Tegafur\uff0cGimeracil and Oteracil Potassium Capsules) is given during radiation therapy and neoadjuvant chemotherapy, oxaliplatin is given during neoadjuvant chemotherapy."
        }, 
        "brief_summary": {
            "textblock": "To investigate the feasibility, safety and tolerability of Preoperative Chemoradiation in\n      Patients With Localized Gastric Cancer. Primary endpoint: R0 resection rate. Secondary\n      endpoint: resection rate, pathological complete regression (pCR), effectiveness and safety\n      of regime, disease free survival(DFS) and overall survival(OS)."
        }, 
        "brief_title": "Neoadjuvant Chemotherapy Plus Chemoradiation in Patients With Potentially Resectable Gastric Carcinoma", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Gastric Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Stomach Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "The prognosis of gastric cancer is poor partially due to low R0 resection rate. Neoadjuvant\n      chemoradiotherapy  was reported to be effective in this setting by several phase II studies.\n      The investigators aim to evaluate the efficacy and toxicity of neoadjuvant chemoradiotherapy\n      in a prospective phase II study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        1.18 \u2264 age \u2264 70, Male or Female; 2.Minimum life expectancy of 6 months; 3.Patients with\n        localized, histologically confirmed gastric or gastroesophageal adenocarcinoma; 4.Patients\n        must have a performance status of < 2 Eastern Cooperative Oncology Group (ECOG); 5.No\n        prior major surgery of the stomach or radiation therapy to the stomach or immunotherapy or\n        chemotherapy; 6.CT or MRI, endorectal ultrasonography (EUS), laparoscopic exploration are\n        required to stage; 7.Without other benign diseases such as lung, kidney, liver infections;\n        8.Without participating other clinical trials; 9.Patient must sign an informed consent\n        prior to study entry; 10.Patients must have adequate bone marrow function (defined as\n        peripheral absolute granulocyte count of >1,500/\u00b5L, and platelet count of > 100,000/\u00b5L),\n        adequate liver function (bilirubin <= 1.5 mg/dl), and adequate renal function (creatinine\n        <= 1.5 mg/dl). 11)Patients without cardiac disease , severe uncontrolled diabetes,\n        hypertension, cerebrovascular disease, or infection.\n\n        Exclusion Criteria:\n\n          1. Pregnant women are excluded from study entry due to the potential teratogenic effects\n             of the study treatment;\n\n          2. Female patients who planed to have a baby;\n\n          3. Prior radiation therapy to the stomach, liver or kidney;\n\n          4. Dysfunction of important organs such as liver, kidney or heart; 5.Abnormalities of\n             mental status;\n\n        6.Active coronary artery disease; 7.Cardiac arrhythmia, and need to receive medication\n        therapy; 8.Severe uncontrolled hypertension; 9.Active clinical serious infection; 10.The\n        known human immunodeficiency virus (HIV) infection history; 11.The known central nervous\n        system diseases, including brain metastatic tumors; 12.Patients have had clinical clear\n        gastrointestinal bleeding in 6 months; 13.Drug abuse; 14.Swallowing difficulties for\n        drugs; 15.Poor compliance; 16.Presence of concurrent or previous malignancies (except for\n        cervical carcinoma in situ or basal cell carcinoma of the skin); 17.Presence of peritoneal\n        metastasis, distant organs or lymph nodes metastasis; 18.Presence history of major surgery\n        in the past three months; 19.Poor tolerability; 20.Prior history of medication; 21.allergy\n        for chemotherapeutic drugs."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02024217", 
            "org_study_id": "LAGCCS001"
        }, 
        "intervention": {
            "arm_group_label": "chemoradiotherapy, S1, oxaliplatin", 
            "description": "Radiation: 180 (cGy) /day, D1-5;S1: 50mg/m2,D1-5;", 
            "intervention_name": "S1\uff0coxaliplatin\uff0cradiation", 
            "intervention_type": "Radiation", 
            "other_name": "S1(Tegafur\uff0cGimeracil and Oteracil Potassium Capsules)"
        }, 
        "intervention_browse": {
            "mesh_term": "Oxaliplatin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 25, 2013", 
        "location": {
            "contact": {
                "email": "11111230012@fudan.edu.cn", 
                "last_name": "Guichao Li, MD"
            }, 
            "contact_backup": {
                "email": "liuxw1129@hotmail.com", 
                "last_name": "Xiaowen Liu, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200032"
                }, 
                "name": "Fudan University Shanghai Cancer Center"
            }, 
            "investigator": {
                "last_name": "Zhen Zhang, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study of Neoadjuvant Chemotherapy Wtih S1+Oxaliplatin (SOX) Regimen Followed by Chemoradiation Concurrent With S-1 in Patients With Potentially Resectable Gastric Carcinoma", 
        "other_outcome": [
            {
                "description": "6-8 weeks after Radiation therapy\uff0cwe evaluate the lesion\uff0cif it is resectable\uff0cwe will give surgical therapy\uff0c", 
                "measure": "resection rate", 
                "safety_issue": "Yes", 
                "time_frame": "6-8 Weeks"
            }, 
            {
                "description": "after surgical therapy\uff0cwe followup the patients and stat the recurrence and death and calculate the disease-free survival", 
                "measure": "disease-free survival", 
                "safety_issue": "Yes", 
                "time_frame": "up to 36 months"
            }, 
            {
                "description": "after surgical therapy\uff0cwe followup the patients and stat the recurrence and death and calculate the over-all survival", 
                "measure": "over-all survival", 
                "safety_issue": "Yes", 
                "time_frame": "up to 36 months"
            }
        ], 
        "overall_contact": {
            "email": "11111230012@fudan.edu.cn", 
            "last_name": "Guichao Li, MD", 
            "phone": "862164175590", 
            "phone_ext": "1606"
        }, 
        "overall_contact_backup": {
            "email": "liuxw1129@hotmail.com", 
            "last_name": "Xiaowen Liu, MD"
        }, 
        "overall_official": {
            "affiliation": "Fudan University", 
            "last_name": "Zhen Zhang, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "6-8 weeks after Radiation therapy\uff0cwe evaluate the lesion\uff0cif it is resectable\uff0cwe will give surgical therapy\uff0c", 
            "measure": "R0 resection rate", 
            "safety_issue": "Yes", 
            "time_frame": "6-8 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02024217"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "Zhen Zhang", 
            "investigator_title": "Chairman of Department of Radiation Oncology Fudan University Shanghai Cancer Center", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "results_reference": {
            "PMID": "19139439", 
            "citation": "Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, K\u00f6nigsrainer A, Budach W, Wilke H. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009 Feb 20;27(6):851-6. doi: 10.1200/JCO.2008.17.0506. Epub 2009 Jan 12."
        }, 
        "secondary_outcome": {
            "description": "after neoadjuvant chemotherapy and chemoradiotherapy\uff0cwe evaluate the side effects , and record the side effects", 
            "measure": "safety and tolerability of the treatment regimen", 
            "safety_issue": "Yes", 
            "time_frame": "up to 10 weeks"
        }, 
        "source": "Fudan University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fudan University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}